Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer

被引：54
|
作者：
Hasegawa, Takahiro [1 ]
Uno, Hajime [2 ]
Wei, Lee-Jen [3 ]
机构：
[1] Shionogi, Osaka, Japan
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Harvard Univ, Boston, MA 02115 USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2016年 / 374卷 / 05期
关键词：
D O I：
10.1056/NEJMc1514790
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：492 / 492
页数：1
相关论文
共 50 条
  • [1] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
    Borghaei, H.
    Paz-Ares, L.
    Horn, L.
    Spigel, D. R.
    Steins, M.
    Ready, N. E.
    Chow, L. Q.
    Vokes, E. E.
    Felip, E.
    Holgado, E.
    Barlesi, F.
    Kohlhaeufl, M.
    Arrieta, O.
    Burgio, M. A.
    Fayette, J.
    Lena, H.
    Poddubskaya, E.
    Gerber, D. E.
    Gettinger, S. N.
    Rudin, C. M.
    Rizvi, N.
    Crino, L.
    Blumenschein, G. R.
    Antonia, S. J.
    Dorange, C.
    Harbison, C. T.
    Finckenstein, F. Graf
    Brahmer, J. R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17): : 1627 - 1639
  • [2] Nivolumab: A Review in Advanced Nonsquamous Non-Small Cell Lung Cancer
    Keating, Gillian M.
    [J]. DRUGS, 2016, 76 (09) : 969 - 978
  • [3] Nivolumab: A Review in Advanced Nonsquamous Non-Small Cell Lung Cancer
    Gillian M. Keating
    [J]. Drugs, 2016, 76 : 969 - 978
  • [4] Nivolumab plus Ipilimumab in Non-Small-Cell Lung Cancer
    Bersanelli, Melissa
    Tiseo, Marcello
    Banna, Giuseppe L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (09): : 874 - 875
  • [5] Effect and biomarker of Nivolumab for non-small-cell lung cancer
    Wang, Li
    Zhao, Deze
    Qin, Kang
    Ul Rehman, Faisal
    Zhang, Xiaochun
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2019, 117
  • [6] Nivolumab plus ipilimumab in non-small-cell lung cancer
    Reck, Martin
    Borghaei, Hossein
    O'Byrne, Kenneth J.
    [J]. FUTURE ONCOLOGY, 2019, 15 (19) : 2287 - 2302
  • [7] Nivolumab in non-small-cell lung cancer with EGFR mutation
    Yoshida, H.
    Kim, Y. H.
    Ozasa, H.
    Nagai, H.
    Sakamori, Y.
    Tsuji, T.
    Nomizo, T.
    Yasuda, Y.
    Funazo, T.
    Hirai, T.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 (03) : 777 - 778
  • [8] Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer
    Sugawara, S.
    Lee, J-S
    Kang, J-H
    Kim, H. R.
    Inui, N.
    Hida, T.
    Lee, K. H.
    Yoshida, T.
    Tanaka, H.
    Yang, C-T
    Nishio, M.
    Ohe, Y.
    Tamura, T.
    Yamamoto, N.
    Yu, C-J
    Akamatsu, H.
    Namba, Y.
    Sumiyoshi, N.
    Nakagawa, K.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 (09) : 1137 - 1147
  • [9] Nivolumab for squamous-cell non-small-cell lung cancer
    Yaqub, Farhat
    [J]. LANCET ONCOLOGY, 2015, 16 (07): : E319 - E319
  • [10] SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
    Borghaei, H.
    de Marinis, F.
    Dumoulin, D.
    Reynolds, C.
    Theelen, W. S. M. E.
    Percent, I.
    Calderon, V. Gutierrez
    Johnson, M. L.
    Madroszyk-Flandin, A.
    Garon, E. B.
    He, K.
    Planchard, D.
    Reck, M.
    Popat, S.
    Herbst, R. S.
    Leal, T. A.
    Shazer, R. L.
    Yan, X.
    Harrigan, R.
    Peters, S.
    [J]. ANNALS OF ONCOLOGY, 2024, 35 (01) : 66 - 76
12345